Arcutis Reports Tomorrow Having Already Told Investors Exactly What Growth to Expect

Arcutis Biotherapeutics (NASDAQ: ARQT) reports first-quarter 2026 earnings after the close on May 6, with analysts expecting the commercial-stage dermatology company to post its third consecutive quarterly profit. The central question is whether ARQT can sustain the profitability momentum that began in Q3 2025, driven by accelerating sales of its flagship ZORYVE franchise across multiple indications. With the stock trading near its 200-day moving average and analyst price targets implying 48% upside, this report will test whether the company's transition from clinical-stage biotech to profitable commercial operation is durable or premature.

Part 1: Earnings Preview

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases, with its lead product ZORYVE (roflumilast) approved for plaque psoriasis and atopic dermatitis. The company has built a U.S. specialty commercial infrastructure and is advancing a pipeline of next-generation roflumilast formulations targeting additional dermatology indications.

ARQT is scheduled to report Q1 2026 results after the close on May 6, with the consensus estimate calling for EPS of -$0.02 from three analysts. Estimates range from -$0.08 to $0.05, reflecting significant uncertainty about whether the company can maintain profitability. The company most recently reported Q4 2025 EPS of $0.13, crushing estimates of $0.03 by $0.10 and marking its second consecutive profitable quarter. Compared to the year-ago quarter (Q1 2025), when ARQT posted -$0.20 per share, the current estimate of -$0.02 represents a +90% improvement, though it would snap the two-quarter profit streak if realized.

Three key themes define this earnings story:

ZORYVE Commercial Momentum: The primary question is whether ZORYVE revenue growth can sustain profitability. The company recently submitted a supplemental NDA to expand ZORYVE cream's atopic dermatitis indication down to infants as young as 3 months, which could significantly expand the addressable market. Additionally, ZORYVE cream received a strong recommendation in the American Academy of Dermatology's first-ever pediatric atopic dermatitis guidelines, providing important clinical validation. Investors will scrutinize Q1 prescription trends, market share gains, and management's updated revenue guidance to assess whether the commercial trajectory supports the Street's full-year EPS estimate of $0.18.

Path to Sustained Profitability: After posting back-to-back profitable quarters in Q3 and Q4 2025, the consensus estimate of -$0.02 for Q1 suggests analysts expect a modest loss, potentially due to seasonal factors or increased investment. The wide estimate range (-$0.08 to $0.05) indicates disagreement about operating leverage and expense management. Management commentary on gross-to-net dynamics, sales force productivity, and operating expense discipline will be critical to understanding whether 2026 can deliver the $0.18 full-year profit analysts project—and the $1.02 expected in 2027.

Pipeline Progress and Label Expansion: Beyond the base business, investors will watch for updates on the pediatric atopic dermatitis label expansion timeline and any progress on next-generation roflumilast formulations (ointments and foams) for seborrheic dermatitis and other indications. Successful label expansions and pipeline advancement would support the bull case that ARQT is building a durable, multi-product dermatology franchise rather than a single-product story.

Analyst commentary ahead of the release is constructive. Mizuho Securities recently reiterated a Buy rating, and the consensus among nine analysts is overwhelmingly positive with six Strong Buys and one Moderate Buy. The average price target of $34.75 implies 48% upside from current levels, suggesting analysts believe the profitability inflection is real and the commercial opportunity remains underappreciated. However, the wide estimate range for Q1 indicates uncertainty about near-term execution, making management's guidance and commentary on the May 6 call critical to maintaining confidence in the growth trajectory.

Part 2: Historical Earnings Performance

Arcutis has demonstrated a clear trend of beating earnings estimates over the past four quarters, with the magnitude of beats accelerating dramatically. In Q1 2025, the company posted -$0.20 versus an estimate of -$0.21, a modest 4.76% beat. The outperformance expanded significantly in Q2 2025, with actual EPS of -$0.13 beating the -$0.18 estimate by 27.78%. The inflection came in Q3 2025, when ARQT delivered its first profitable quarter at $0.06 per share against an estimate of -$0.10—a stunning 160% beat that marked the company's transition to profitability. The momentum continued in Q4 2025, with EPS of $0.13 crushing the $0.03 estimate by 333%, more than quadrupling expectations.

The pattern reveals a company that has consistently exceeded Wall Street's expectations by widening margins, suggesting analysts have been too conservative in modeling the commercial ramp of ZORYVE and the operating leverage in the business model. The progression from small beats on losses to massive beats on profits indicates the commercial launch is outperforming internal and external forecasts. However, the consensus estimate of -$0.02 for Q1 2026 suggests analysts are taking a more cautious stance, potentially expecting seasonal softness or increased investment that could temporarily interrupt the profit streak.

The four-quarter beat streak, combined with the dramatic improvement from -$0.20 a year ago to an expected -$0.02 this quarter, establishes a high bar for management. Investors will likely react negatively to any miss or even an in-line result, given the established pattern of significant outperformance. Conversely, another beat—particularly one that delivers positive EPS rather than the expected small loss—could reinforce confidence that ARQT has achieved sustainable profitability and trigger further multiple expansion.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Arcutis typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 5.67% and Day +1 move of 7.56%. The most dramatic reaction came after the Q3 2025 report, when the stock surged 27.04% on Day 0 in anticipation, followed by a more modest 1.36% gain on Day +1 after the company delivered its first profitable quarter. The Q4 2025 report was more muted, with only a 0.11% Day 0 move but a 5.78% Day +1 gain after the company posted another beat. Earlier reports in 2025 showed mixed reactions, including a 7.07% Day 0 decline ahead of Q1 2025 results and an 8.07% Day +1 drop after Q2 2025, despite both quarters beating estimates.

The average Day +1 range of 12.56% indicates substantial intraday volatility following earnings releases, suggesting the market struggles to immediately price in the implications of results and guidance. The pattern shows that positive earnings surprises don't always translate to immediate gains—execution on guidance and forward commentary appear equally important. Given the stock's recent pattern of massive beats and the transition to profitability, investors should expect heightened volatility around this release, particularly if results challenge the narrative that ARQT has achieved sustainable profitability. The 7.56% average Day +1 move suggests a potential swing of roughly $1.75 in either direction from the current $23.42 price.

Part 2.2: Options Market Expected Move

The options market is pricing in a 0.00% expected move for the May 15 expiration, which appears to be a data anomaly given the stock's historical 7.56% average Day +1 move around earnings. With average implied volatility of 113.94% and total open interest of just 382 contracts, the options market for ARQT appears relatively illiquid, making the expected move calculation unreliable. Investors should rely more heavily on the historical 5.67% Day 0 and 7.56% Day +1 average moves when assessing potential post-earnings volatility.

Part 3: What Analysts Are Saying

Analyst sentiment on Arcutis is decidedly bullish, with a consensus rating of 4.44 out of 5.00—firmly in Strong Buy territory. The breakdown shows six Strong Buys, one Moderate Buy, and two Hold ratings among nine covering analysts, with zero Sell or Strong Sell ratings. This lopsided positive stance reflects confidence in the company's commercial execution and profitability trajectory. The average price target of $34.75 implies 48% upside from the current price of $23.42, with estimates ranging from a low of $33.00 to a high of $36.00. The tight range of price targets (just $3.00 spread) suggests analysts are aligned on valuation, with even the most conservative target implying 41% upside.

Sentiment has remained unchanged over the past month, with the same 4.44 rating and identical distribution of recommendations. This stability suggests analysts are waiting for the Q1 report to reassess their views rather than making preemptive changes. The lack of recent downgrades despite the stock's strong performance indicates conviction that the profitability inflection is sustainable. Mizuho Securities' recent Buy reiteration reinforces the positive stance, though the absence of fresh upgrades or raised price targets suggests the Street may be taking a wait-and-see approach to the Q1 results.

The 48% implied upside from the consensus target is substantial and reflects the view that ARQT remains undervalued despite the recent transition to profitability. Analysts appear to be pricing in sustained revenue growth from ZORYVE, successful label expansions, and continued operating leverage that drives the projected $0.18 EPS in 2026 and $1.02 in 2027. However, the two Hold ratings serve as a reminder that not all analysts are convinced the current valuation fully discounts execution risk, particularly given the wide Q1 estimate range and the uncertainty about whether profitability can be maintained quarter after quarter.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 24% Sell signal, representing a significant improvement from the 40% Sell signal one week ago but a deterioration from the 8% Sell signal one month ago. This recent volatility in the technical indicator suggests the stock is in a transitional phase, with short-term momentum improving even as the intermediate-term picture remains cautious.

Timeframe Analysis:

• Short-term (Hold): Neutral reading suggests near-term momentum has stabilized after recent weakness, with the stock finding support ahead of earnings
• Medium-term (50% Sell): Moderate sell signal indicates consolidation or mild downtrend pressure in the intermediate timeframe, reflecting the stock's inability to break above resistance
• Long-term (Hold): Neutral long-term signal suggests the broader trend remains balanced, with neither bulls nor bears in clear control

Trend Characteristics: The Minimum strength and Weakest direction readings indicate the current trend environment is fragile and lacks conviction heading into earnings, suggesting the stock is vulnerable to sharp moves in either direction based on results and guidance.

The stock is currently trading at $23.42, positioned above its 5-day moving average of $23.17 and 10-day moving average of $23.24, indicating short-term momentum is positive. However, the price sits below the 20-day ($23.81), 50-day ($23.76), and 100-day ($25.61) moving averages, confirming the medium-term weakness reflected in the 50% Sell signal. The stock is above its 200-day moving average of $22.93, suggesting long-term support remains intact despite recent consolidation.

Key resistance levels to watch are the 20-day and 50-day moving averages in the $23.75-$23.80 range, which the stock has struggled to reclaim. A strong earnings beat could propel ARQT back above these levels and target the 100-day moving average at $25.61. Conversely, a disappointment could send the stock back toward the 200-day moving average at $22.93, which has served as a floor. The technical setup is neutral to slightly cautious heading into earnings, with the improving short-term momentum offset by persistent medium-term weakness. The fragile trend characteristics and Weakest direction reading suggest the stock lacks a strong directional bias, making the earnings report the likely catalyst to break the current consolidation pattern. Given the 48% upside to analyst price targets and the stock's history of beating estimates, the risk-reward may favor bulls, but the technical picture offers little conviction either way until results provide clarity.